Lobbying client
TRYGG PHARMA, INC.
Pharmaceutical research and development.
The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 2 of its records are shown together here.
Filings
14
Filed by
2
Reported in-house
—
Reported by firms
$340,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2012 to 2014
Filings
4 filings for 2012, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
4th Quarter - Report 4th Quarter 2012
|
ENGEL & NOVITT, LLP | $30,000 reported |
|
4th Quarter - Report 4th Quarter 2012
|
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) | $60,000 reported |
|
Registration 4th Quarter 2012
|
ENGEL & NOVITT, LLP | — reported |
|
Registration 4th Quarter 2012
|
FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) | 7 | $300,000 |
| ENGEL & NOVITT, LLP | 5 | $40,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Health Issues | HCR | 12 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.